LTG 305
Alternative Names: LTG-305Latest Information Update: 21 Aug 2024
At a glance
- Originator Latigo Biotherapeutics
- Class Non-opioid analgesics
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 21 Aug 2024 Preclinical trials in Pain in USA (PO) prior to August 2024 (Latigo Biotherapeutics pipeline, August 2024)
- 16 Aug 2024 Latigo Biotherapeutics plans a phase I safety and pharmacokinetics trial in healthy subjects in New Zealand (PO) (NCT06554574)
- 15 Sep 2022 Latigo Biotherapeutics has patent protection for "Methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use (WO2022192487A2) worldwide